CytomX Therapeutics Inc. Insider Trading

CTMX

Last 12 months

Insiders sold $1.69M and bought nothing on the open market.

72% of the selling was scheduled in advance under 10b5-1 plans. Chief Medical Officer Yu-Waye Chu sold 137K on Mar 17, 10% of their stake, outside a plan. The last open-market buy by an executive or director was in Mar 2023.

Net open-market

−$1.69M

0 buys · 6 sales

Under a 10b5-1 plan

72%

of the value sold

Insiders who bought / sold

0 / 4

executives and directors

Last open-market buy

Mar 2023

Mar 29, 2023

Get an email when CTMX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jun 15	Christopher Ogden Chief Financial Officer	SoldNo plan	1,624	$3.05	5K	0.5%	Form 4
Mar 17	Yu-Waye Chu Chief Medical Officer	SoldNo plan	21,279	$6.42	137K	10%	Form 4
Mar 17	Sean A. McCarthy CEO	Sold10b5-1 plan	118,969	$6.42	764K	9.2%	Form 4
Mar 17	Marcia Belvin SVP, Chief Scientific Officer	SoldNo plan	31,492	$6.42	202K	9.5%	Form 4
Mar 17	Christopher Ogden Chief Financial Officer	SoldNo plan	19,323	$6.42	124K	6.1%	Form 4
Nov 6, 2025	Sean A. McCarthy CEO	Sold10b5-1 plan	101,793	$4.54	462K	7.9%	Form 4
Jun 13, 2025 – Jun 16, 2025	Christopher Ogden Chief Financial Officer	SoldNo plan 2 parts	12,255	$2.72 average	33K	5.1%	Form 4
Jun 16, 2025	Marcia Belvin SVP, Chief Scientific Officer	SoldNo plan	13,884	$2.69	37K	4.9%	Form 4
Jun 16, 2025	Sean A. McCarthy CEO	SoldNo plan	55,511	$2.69	149K	4.5%	Form 4
Mar 18, 2025	Sean A. McCarthy CEO	SoldNo plan	37,656	$0.60	23K	3.3%	Form 4
Mar 18, 2025	Christopher Ogden Chief Financial Officer	SoldNo plan	8,551	$0.60	5K	4.1%	Form 4
Mar 18, 2025	Yu-Waye Chu Chief Medical Officer	SoldNo plan	4,025	$0.60	2K	2.9%	Form 4
Mar 18, 2025	Lloyd A Rowland General Counsel	SoldNo plan	10,203	$0.60	6K	7.8%	Form 4
Mar 18, 2025	Marcia Belvin SVP, Chief Scientific Officer	SoldNo plan	19,512	$0.60	12K	7.3%	Form 4

Jun 15No plan
Christopher Ogden
Chief Financial Officer · sold 1,624 at $3.05
5K
0.5% of stake
Mar 17No plan
Yu-Waye Chu
Chief Medical Officer · sold 21,279 at $6.42
137K
10% of stake
Mar 1710b5-1 plan
Sean A. McCarthy
CEO · sold 118,969 at $6.42
764K
9.2% of stake
Mar 17No plan
Marcia Belvin
SVP, Chief Scientific Officer · sold 31,492 at $6.42
202K
9.5% of stake
Mar 17No plan
Christopher Ogden
Chief Financial Officer · sold 19,323 at $6.42
124K
6.1% of stake
Nov 6, 202510b5-1 plan
Sean A. McCarthy
CEO · sold 101,793 at $4.54
462K
7.9% of stake
Jun 13, 2025 – Jun 16, 2025No plan
Christopher Ogden
Chief Financial Officer · sold 12,255 at avg $2.72
33K
5.1% of stake
Jun 16, 2025No plan
Marcia Belvin
SVP, Chief Scientific Officer · sold 13,884 at $2.69
37K
4.9% of stake
Jun 16, 2025No plan
Sean A. McCarthy
CEO · sold 55,511 at $2.69
149K
4.5% of stake
Mar 18, 2025No plan
Sean A. McCarthy
CEO · sold 37,656 at $0.60
23K
3.3% of stake
Mar 18, 2025No plan
Christopher Ogden
Chief Financial Officer · sold 8,551 at $0.60
5K
4.1% of stake
Mar 18, 2025No plan
Yu-Waye Chu
Chief Medical Officer · sold 4,025 at $0.60
2K
2.9% of stake
Mar 18, 2025No plan
Lloyd A Rowland
General Counsel · sold 10,203 at $0.60
6K
7.8% of stake
Mar 18, 2025No plan
Marcia Belvin
SVP, Chief Scientific Officer · sold 19,512 at $0.60
12K
7.3% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch CTMX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with CTMX

CompareIntrinsic value

QUREuniQure N.V.

$23.07-3.35%10

EVFMEvofem Biosciences Inc.

$0.01+0.00%15

CELUCelularity Inc.

$0.81-1.00%0

SCYXScynexis, Inc.

$3.84-2.54%40

SLGLSol-Gel Technologies Ltd.

$66.00+3.43%65

ANABAnaptysBio Inc.

$47.51-0.46%20

KPRXKiora Pharmaceuticals Inc.

$1.66-4.05%10

EMMAEmmaus Life Sciences, Inc.

$0.03-17.50%21

Held by ETFs

CTMX is in 24 US ETFs. The largest of them, with CTMX's weight in each:

Spot a number that looks wrong? Check it in CTMX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing CTMX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.